Recent studies have demonstrated that FANCD2 in HCC cells maintains resistance to DNA-damaging tumor suppression by increasing DNA repair activity, FANCD2 deletion restricts chemoresistance of HCC cells in vitro (Palagyi et al., 2010), and elevated FANCD2 is closely linked to adverse prognosis in HCC (Komatsu et al., 2017), glioma cells (Chen et al., 2021), breast cancer (Fagerholm et al., 2013), colorectal cancer (Ozawa et al., 2010), and non-small-cell lung cancer (Ferrer et al., 2005). This evidence concerns the gene FANCD2 and breast carcinoma.